دورية أكاديمية
أعرض في EDS

Loss of EphA7 Expression in Basal Cell Carcinoma by Hypermethylation of CpG Islands in the Promoter Region.

التفاصيل البيبلوغرافية
العنوان: Loss of EphA7 Expression in Basal Cell Carcinoma by Hypermethylation of CpG Islands in the Promoter Region.
المؤلفون: Liu J; Department of Dermatology, Taixing People's Hospital, Jiangsu Taixing 225400, China., Yu N; Department of Radiotherapy, Taixing People's Hospital, Jiangsu Taixing 225400, China., Feng X; Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China., He Y; Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China., Lv K; Department of Dermatology, Taixing People's Hospital, Jiangsu Taixing 225400, China., Zhu H; Department of Dermatology, Taixing People's Hospital, Jiangsu Taixing 225400, China., Wang J; Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
المصدر: Analytical cellular pathology (Amsterdam) [Anal Cell Pathol (Amst)] 2022 Jan 22; Vol. 2022, pp. 4220786. Date of Electronic Publication: 2022 Jan 22 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Hindawi Country of Publication: United States NLM ID: 101541993 Publication Model: eCollection Cited Medium: Internet ISSN: 2210-7185 (Electronic) Linking ISSN: 22107177 NLM ISO Abbreviation: Anal Cell Pathol (Amst) Subsets: MEDLINE
أسماء مطبوعة: Publication: 2014- : New York : Hindawi
Original Publication: Amsterdam : IOS Press
مواضيع طبية MeSH: Carcinoma, Basal Cell*/genetics , Carcinoma, Basal Cell*/metabolism , CpG Islands* , DNA Methylation* , Receptor, EphA7*/biosynthesis , Receptor, EphA7*/genetics , Receptor, EphA7*/metabolism , Skin Neoplasms*/genetics , Skin Neoplasms*/metabolism, Humans ; Promoter Regions, Genetic
مستخلص: Basal cell carcinoma (BCC) is the most common malignancy worldwide, with increasing incidence. BCCs present low mortality but high morbidity, and its pathogenesis remains unclear. Eph receptors have been implicated in tumorigenesis. EphA7 plays a role as a tumor suppressor in certain cancers. We checked EphA7 expression levels and methylation status in a set of BCCs, benign skin diseases, and compound nevus tissue samples using immunohistochemistry. EphA7 protein was positively expressed in normal basal cells, benign skin diseases, and compound nevus cells, but lost in areas of BCC tissues. We detected hypermethylation in BCC tissue samples with reduced expression of EphA7. There is a significant relationship between the expression level of EphA7 receptor protein and the methylation status of CpG islands in the EphA7 promoter region ( P < 0.001). To our knowledge, this is the first study to report the EphA7 expression profile and hypermethylation of EphA7 in BCC. The role of the EphA7 gene and the status of hypermethylation in tumorigenesis and treatment of BCC warrant further investigation.
Competing Interests: The authors declare that no conflict of interest exists.
(Copyright © 2022 Jie Liu et al.)
References: Cancer. 2009 Jun 15;115(12):2684-92. (PMID: 19396818)
Skinmed. 2014 May-Jun;12(3):176-81. (PMID: 25134314)
Life (Basel). 2020 Sep 30;10(10):. (PMID: 33007931)
Mech Dev. 1997 Nov;68(1-2):173-7. (PMID: 9431814)
J Mammary Gland Biol Neoplasia. 2003 Oct;8(4):475-85. (PMID: 14985642)
Cancer Lett. 2018 Oct 10;434:160-171. (PMID: 30055288)
Cell Death Dis. 2017 Oct 12;8(10):e3122. (PMID: 29022918)
Cancer. 2007 Jan 15;109(2):332-40. (PMID: 17154180)
Eur Rev Med Pharmacol Sci. 2020 Jun;24(11):6139-6149. (PMID: 32572879)
PLoS One. 2008 Jul 23;3(7):e2780. (PMID: 18648668)
Mod Pathol. 2006 Oct;19(10):1369-77. (PMID: 16862074)
Leuk Res. 2017 Aug;59:65. (PMID: 28575698)
J Natl Cancer Inst. 1998 Apr 1;90(7):523-31. (PMID: 9539248)
Hematol Oncol Clin North Am. 2019 Feb;33(1):13-24. (PMID: 30497670)
Prostate. 1999 Dec 1;41(4):275-80. (PMID: 10544301)
Int J Mol Sci. 2016 Sep 26;17(10):. (PMID: 27681722)
Hum Pathol. 2007 Nov;38(11):1649-56. (PMID: 17669470)
Invest New Drugs. 2015 Dec;33(6):1217-24. (PMID: 26365907)
Int J Clin Exp Pathol. 2020 May 01;13(5):1220-1242. (PMID: 32509099)
Sci Rep. 2017 Mar 06;7:43702. (PMID: 28262839)
Development. 1998 Nov;125(21):4195-204. (PMID: 9753674)
Exp Dermatol. 2004 Oct;13(10):643-50. (PMID: 15447725)
Cancer Chemother Pharmacol. 2018 Sep;82(3):541-550. (PMID: 30030583)
Diagn Cytopathol. 2013 Mar;41(3):199-205. (PMID: 21964981)
Mol Med Rep. 2016 Apr;13(4):3190-6. (PMID: 26936314)
Med Oncol. 2012 Dec;29(4):2691-700. (PMID: 22189617)
Oncol Rep. 2004 Mar;11(3):605-11. (PMID: 14767510)
Cytokine Growth Factor Rev. 2004 Dec;15(6):419-33. (PMID: 15561600)
Pharmaceuticals (Basel). 2020 May 08;13(5):. (PMID: 32397088)
Am J Pathol. 2001 Feb;158(2):381-5. (PMID: 11159175)
Brain Res Mol Brain Res. 1999 Dec 10;74(1-2):231-6. (PMID: 10640696)
Curr Opin Cell Biol. 2008 Apr;20(2):194-200. (PMID: 18353626)
Int J Cancer. 2009 Jan 1;124(1):88-94. (PMID: 18821581)
Acta Derm Venereol. 2020 Mar 31;100(6):adv00098. (PMID: 32052850)
Exp Dermatol. 2018 Oct;27(10):1160-1165. (PMID: 30033544)
Oncogene. 2005 Aug 25;24(36):5637-47. (PMID: 16007213)
Biomolecules. 2019 Sep 09;9(9):. (PMID: 31505877)
PLoS One. 2017 Jun 12;12(6):e0175553. (PMID: 28604772)
Med Arch. 2019 Dec;73(6):394-398. (PMID: 32082007)
Stem Cell Res. 2020 Jul 21;47:101914. (PMID: 32738632)
Int Arch Occup Environ Health. 2002 Apr;75(4):272-6. (PMID: 11981662)
Exp Hematol. 2017 Apr;48:72-78. (PMID: 27988259)
Cell Mol Life Sci. 2012 Jun;69(11):1813-42. (PMID: 22204021)
Clin Exp Metastasis. 2003;20(1):59-68. (PMID: 12650608)
BMC Cancer. 2008 Mar 25;8:79. (PMID: 18366728)
Expert Opin Investig Drugs. 2020 Jun;29(6):567-582. (PMID: 32348169)
N Engl J Med. 2005 Nov 24;353(21):2262-9. (PMID: 16306523)
Cell Death Dis. 2019 Jul 4;10(7):514. (PMID: 31273190)
Arch Physiol Biochem. 2020 May 18;:1-7. (PMID: 32421395)
المشرفين على المادة: EC 2.7.10.1 (Receptor, EphA7)
تواريخ الأحداث: Date Created: 20220201 Date Completed: 20220404 Latest Revision: 20220531
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8800629
DOI: 10.1155/2022/4220786
PMID: 35103233
قاعدة البيانات: MEDLINE
الوصف
تدمد:2210-7185
DOI:10.1155/2022/4220786